<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917887</url>
  </required_header>
  <id_info>
    <org_study_id>KRYS-LTFU-01</org_study_id>
    <nct_id>NCT04917887</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-up Protocol</brief_title>
  <official_title>A Prospective, Observational, Long-Term Follow-Up (LTFU) Study to Evaluate the Long-Term Safety of the Krystal Biotech, Inc. Gene Therapy Backbone Products Using HSV-1 Backbone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krystal Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krystal Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this prospective, observational, long-term follow-up (LTFU) study is to&#xD;
      evaluate the long-term safety profile of the gene therapy products evaluated by Krystal&#xD;
      Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least&#xD;
      one dose of investigational product (IP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the guidelines for gene therapy for vectors which may undergo latency/ reactivation,&#xD;
      Krystal Biotech, Inc. has established a Long-Term Follow-up Protocol which will identify and&#xD;
      mitigate the long-term risks to the participants receiving their gene therapy products and&#xD;
      capture delayed adverse events in participants, annually, for 5-years following the last&#xD;
      study visit. Additionally, it will allow the Sponsor to further understand the persistence of&#xD;
      the gene therapy products used in their parent treatment protocols.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">May 25, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events (AE)</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of delayed Adverse Events suspected to be related to a Krystal Biotech HSV-1 vector backbone investigational product.&#xD;
A Serious Adverse Event (SAE) is any untoward medical occurrence (whether considered to be related to gene therapy or not) that:&#xD;
Is fatal&#xD;
Is life-threatening (places the participant at immediate risk of death)&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization&#xD;
Is a persistent or significant disability/incapacity, or&#xD;
Is a congenital abnormality/birth defect</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <condition>Recessive Dystrophic Epidermolysis Bullosa</condition>
  <condition>Dominant Dystrophic Epidermolysis Bullosa</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who received at least one treatment of gene therapy from a Krystal Biotech,&#xD;
        Inc. sponsored study, will be asked to roll-over to this LTFU protocol upon either&#xD;
        premature discontinuation from, or completion of a prior parent treatment protocol.&#xD;
        However, if a participant enrolls in a different Sponsor gene therapy trial during the LTFU&#xD;
        phase this participant will be dropped out from the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult and pediatric participants who received at least one gene therapy treatment&#xD;
             in a previous Krystal Biotech, Inc. sponsored study, and have discontinued or&#xD;
             completed the parent treatment protocol (which do not have the LTFU embedded into the&#xD;
             parent protocol), as applicable.&#xD;
&#xD;
          -  Consent/Assent must be obtained by the participants (and, parental/legal&#xD;
             representative, when applicable) prior to any study-related data being collected.&#xD;
&#xD;
          -  Participant is willing and able to adhere to the protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who enroll into a non-Krystal Biotech, Inc. interventional gene therapy&#xD;
             clinical trial will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brittani Agostini</last_name>
    <phone>4125865830</phone>
    <email>bagostini@krystalbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mission Dermatology Center</name>
      <address>
        <city>Rancho Santa Margarita</city>
        <state>California</state>
        <zip>92688</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guida Pinto</last_name>
      <phone>949-858-3376</phone>
      <phone_ext>108</phone_ext>
      <email>gpinto.missionderm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shireen Guide, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sinem Bagci</last_name>
      <phone>650-484-6878</phone>
      <email>isbagci@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Marinkovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Skin Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edilmary Urdaneta</last_name>
    </contact>
    <investigator>
      <last_name>Mercedes Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

